Biotech sector has performed better than the broader healthcare space this year. And within the biotech sector, smaller companies have done much better than their larger counterparts.

Thanks to tax reform, large healthcare companies are now able to access billions of dollars of cash that was parked overseas. Lower tax rates are also helping these companies.

Thus, cash rich biotech and pharma giants are looking to acquire smaller, innovative biotech companies, even at hefty premiums, to build their pipelines.

The space has witnessed very strong M&A activity this year and the trend is expected to continue in the coming months.

There have been more than $190 billion worth of biotech and pharma deals announced globally so far this year, according to Dealogic, on track to exceed the record of $315 billion set in 2015.

Further, the FDA has approved many innovative drugs and therapies in recent months in areas like cancer treatment, gene therapy etc. Due to these innovative drugs, some of the earlier blockbuster drugs are no longer in demand and bigger companies are looking for new successful drugs.

Which ETFs are best positioned to benefit from this trend? Find out in the video above where we highlight the iShares Nasdaq Biotechnology ETF (IBB), the SPDR S&P Biotech ETF (XBI) and  the First Trust NYSE Biotechnology ETF (FBT).

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ISHARES NDQ BIO (IBB): ETF Research Reports

FT-AMEX BIOTEC (FBT): ETF Research Reports

SPDR-SP BIOTECH (XBI): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Source: Custom News Article from Zacks Investment Research for ETFHeatMap.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here